These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture. Miller RG Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361 [TBL] [Abstract][Full Text] [Related]
3. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women]. Gorai I; Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077 [TBL] [Abstract][Full Text] [Related]
4. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Cotté FE; Fautrel B; De Pouvourville G Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486 [TBL] [Abstract][Full Text] [Related]
5. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. Ohta H Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613 [TBL] [Abstract][Full Text] [Related]
7. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755 [TBL] [Abstract][Full Text] [Related]
8. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D]. Grazio S; Morović-Vergles J Reumatizam; 2007; 54(2):89-92. PubMed ID: 18351154 [TBL] [Abstract][Full Text] [Related]
9. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665 [TBL] [Abstract][Full Text] [Related]
10. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Adachi JD; Hanley DA; Lorraine JK; Yu M Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204 [TBL] [Abstract][Full Text] [Related]
11. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Papapoulos S; Makras P Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):514-23. PubMed ID: 18714329 [TBL] [Abstract][Full Text] [Related]
12. [Risedronate (Actonel)--from randomized clinical trials to real life]. Anić B Reumatizam; 2007; 54(2):85-6. PubMed ID: 18351152 [No Abstract] [Full Text] [Related]
13. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate]. Anić B; Grazio S Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557 [TBL] [Abstract][Full Text] [Related]
14. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid]. Takata S Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142 [No Abstract] [Full Text] [Related]
15. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. Davison KS; Kendler DL; Ammann P; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; McClung MR; Olszynski WP; Yuen CK Am J Med; 2009 Nov; 122(11):992-7. PubMed ID: 19854322 [TBL] [Abstract][Full Text] [Related]